Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
Detailed Phase II results are expected in the first half of 2024. Image Credit: Net Vector / Shutterstock.
Source: Pharmaceutical Technology
4D-150 is an intravitreal vector-based therapy developed using the therapeutic vector evolution platform as an adeno-associated virus vector to deliver an anti-VEGF transgene that expresses both aflibercept and a VEGF-C inhibitory RNAi, to treat wet AMDAMD. Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Recombinant Human Erythropoietin Injection in Anemia in Chronic Kidney Disea... GlobalData Source: Pharmaceutical Technology
View allCompanies IntelligenceBayer AG4D Molecular Therapeutics IncCytivaChugai Co.,Ltd.Regeneron GmbHView all
The multicentre, randomised Phase I/II PRISM trial (NCT05197270) has completed enrolment for the open-label Phase II dose expansion stage. The trial will assess the safety and efficacy of 4D-150 at two dose levels in 50 patients. The interim reported data demonstrated no treatment-related adverse reactions. Detailed results are expected in the first half of 2024, as per the company’s press release.
4DMT plans to start Phase III trial discussions with the US’ FDA in Q4 2023, with a trial update planned for Q1 2024.
4DMT CEO David Kirn also provided updates on their other pipeline candidates, stating: “We believe that 4D-150’s differentiated profile has the potential to also drive rapid enrolment in our diabetic macular oedema (DME) programme, and we expect to enrol our first patient in the Phase II SPECTRA trial in Q3 2023. There have been an increasing number of trials for wet AMDAMD, with GlobalData forecasting the AMD market to expand to $19.8bn in 2028. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
Source: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy